ArticleOncology letters2012
Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds.
Article in Oncology letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 42 citations in OpenAlex.
- Metabolic Signaling in the Tumor Microenvironment.Cancers · 2025Review
- Lead Borate Nanoparticles Induce Apoptotic Gene Activity in P53 Mutant Cancer Cells.Biological trace element research · 2022Article
- Article
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity.Cardiovascular drugs and therapy · 2020Review
- AMPK Activation of Apoptotic Markers in Human Breast Cancer Cell Lines with Different p53 Backgrounds: MCF-7, MDA-MB-231 and T47D Cells.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.Investigational new drugs · 2018Article
- Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer.Oncotarget · 2017Article
- Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway.Oncotarget · 2017Article
- Progesterone suppresses the invasion and migration of breast cancer cells irrespective of their progesterone receptor status - a short report.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- Entosis Is Induced by Glucose Starvation.Cell reports · 2017Article
- Dissecting the role of AMP-activated protein kinase in human diseases.Acta pharmaceutica Sinica. B · 2017Review
- DeSigN: connecting gene expression with therapeutics for drug repurposing and development.BMC genomics · 2017Article
- AMP-activated protein kinase and energy balance in breast cancer.American journal of translational research · 2017Review
- Differential crosstalk between the AMPK and PI3K/Akt pathways in breast cancer cells of differing genotypes: Leptin inhibits the effectiveness of AMPK activation.Oncology reports · 2015Article
- Exometabolom analysis of breast cancer cell lines: Metabolic signature.Scientific reports · 2015Article
- Article
- Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer?International neurourology journal · 2015Review
- The double-edged sword of AMPK signaling in cancer and its therapeutic implications.Archives of pharmacal research · 2015Review
- Article
- TRAF4 participates in Wnt/β-catenin signaling in breast cancer by upregulating β-catenin and mediating its translocation to the nucleus.Molecular and cellular biochemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains a therapeutic challenge, and this has intensified the search for new drug targets. The AMP-activated protein kinase (AMPK) signalling pathway is emerging as having potential for intervention. We assessed the possible different effects of AMPK action on breast cancer cells by studying their impact on proliferation, apoptosis and the mitochondrial membrane potential in three breast cancer cell lines (MCF-7, MDA-MB-231 and T47D) differing in their p53 and estrogen receptor (ER) status. Activation of AMPK by 5-aminoimidazole carboxamide ribonucleotide (AICAR) and phenformin elicited clear anti-proliferative effects in all breast cancer cell lines, but with differences in sensitivity. However, the anti-proliferative effects were accompanied by varying responses between the different cells, with a marked cell cycle arrest effect in T47D cells and an apoptotic effect in MCF-7 and MDA-MB-231 cells. The mitochondrial apoptotic pathway was potentially involved in all cell lines. These results suggest that AMPK potentially serves as a therapeutic target in breast cancer, but one which may be dependent on the genetic background of the cancer cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.